Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
TERMINATED
NCT03226821
PHASE4

Body Composition and Adipose Tissue in HIV

Sponsor: Columbia University

View on ClinicalTrials.gov

Summary

In this study, the investigators will examine the effect of therapy with the Growth Hormone Releasing Hormone (GHRH) analog tesamorelin on body composition in patients with HIV lipodystrophy and central adiposity. This study is a single arm prospective study of tesamorelin therapy of patients with HIV lipodystrophy. Subjects will do body composition testing, adipose tissue biopsy, metabolic rate measurements and insulin sensitivity assessment before, 6 and 12 months after daily injections of tesamorelin 2 mg by subcutaneous injection.

Official title: Body Composition and Adipose Tissue in HIV Lipodystrophy: Effects of Tesamorelin Therapy

Key Details

Gender

All

Age Range

18 Years - 68 Years

Study Type

INTERVENTIONAL

Enrollment

6

Start Date

2018-02-07

Completion Date

2025-04-30

Last Updated

2026-05-19

Healthy Volunteers

No

Interventions

DRUG

Tesamorelin

Patients will be treated with tesamorelin 2 mg by subcutaneous injection daily

Locations (1)

Neuroendocrine Unit and Pituitary Center, Columbia University

New York, New York, United States